Janssen focuses cardiometabolic R&D on prevention, cure and interception

January 31, 2017 Christoph Graener

With readouts in important trials of key drugs Invokana and Xarelto on the horizon, Dr. James F. List, Global Therapeutic Area Head of Cardiovascular and Metabolism, has plenty of reasons for insomnia. Speaking at Biotech Showcase, List explained to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, how he is also looking for assets designed to prevent, cure or even intercept the progression of key diseases such as obesity and NASH.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: James F. List – Global Therapeutic Area Head of Cardiovascular & Metabolism (CVM), Janssen

Previous Article
BioNTech’s Sean Marett explains Genentech deal rationale
BioNTech’s Sean Marett explains Genentech deal rationale

Chief operating officer of BioNTech, Sean Marett, talks about the German firm's recent co-development deal ...

Next Article
AiCuris seeks partners for antibacterial programs
AiCuris seeks partners for antibacterial programs

AiCuris CEO Holger Zimmermann talks about the company's journey to becoming a clinical biotech company sinc...